Back to top
more

Acorda Therapeutics, Inc. (ACOR)

(Delayed Data from NSDQ)

$11.74 USD

11.74
1,452,260

+1.16 (10.96%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.74 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Teva (TEVA) Q4 Earnings: What's in Store for the Stock?

Teva Pharmaceutical Industries Ltd. (TEVA) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.

    Can Humana (HUM) Pull a Surprise This Earnings Season?

    Humana Inc. (HUM) will release fourth-quarter 2016 results on Feb 8, before the market opens.

      Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?

      Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.

        GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?

        GW Pharmaceuticals plc (GWPH) is scheduled to report first-quarter fiscal 2017 results on Feb 7, before the opening bell.

          Implied Volatility Surging for Acorda Therapeutics (ACOR) Stock Options

          Investors in Acorda Therapeutics, Inc. (ACOR) need to pay close attention to the stock based on moves in the options market lately.

            Allergan (AGN) Q4 Earnings: What's in Store for the Stock?

            Allergan plc (AGN) will be reporting fourth-quarter 2016 earnings on Feb 8, before the market opens. Last quarter, the company delivered a negative earnings surprise of 7.00%.

              GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?

              GlaxoSmithKline plc (GSK) is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.

                The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma

                The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma

                  Arpita Dutt headshot

                  Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?

                  The Q4 earnings season has started on a good note with both earnings and revenue growth improving compared to recent quarters.

                    Kura Oncology Starts Dosing Patients in Phase II CMML Study

                    Kura Oncology (KURA) dosed the first patient in a phase II study on tipifarnib for the treatment of chronic myelomonocytic leukemia.

                      What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?

                      In December, Clovis received the FDA nod for its first product, Rubraca, which sent its shares soaring.

                        3 Biotech Stocks to Turn the Tide This Earnings Season

                        The biotech sector has strong fundamentals, and healthy product pipelines.